Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Albipagrastim alfa for prevention of neutropenia in neoadjuvant breast cancer therapy
ChiCTR2600123897Phase 4Not yet recruiting
- Sponsor
- Southwest Medical University
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rHSA-GCSF in breast cancer, sponsored by Southwest Medical University. Primary endpoint: Safety. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
rHSA-GCSF
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600123897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123897.